Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2021-12-01
|
| Seri Bilgileri: | Pharmaceutics |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1999-4923/14/1/41 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|